Drug intelligence / Profile preview

Bepra

Development stage: Unknown
Lead developer: Global Napi Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Bepra is a proton pump inhibitor (PPI) medication containing rabeprazole sodium (20 mg), developed and marketed by the Egyptian company Global Napi Pharmaceuticals. It works by decreasing the amount of acid produced in the stomach through the inhibition of the gastric H+/K+-ATPase (proton pump). Bepra is approved for the treatment of gastro-oesophageal reflux disease (GORD), peptic ulcers (including gastric and duodenal ulcers), and is used in combination with antibiotics for the eradication of *Helicobacter pylori* infection. It is an oral small molecule drug intended for adult use.

Brand names: Bepra
Other names: rabeprazole sodium

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Bepra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bepra.

Explore the full profile